Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 4:59 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 1,891,167 4.7% | 682,116 (+56.42%) | View |
| 2023-02-14 4:30 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III L.P. | 4,230,621 9.99% | 2,025,353 (+91.84%) | View |
| 2023-02-14 3:05 pm Sale | 13G | Viridian Therapeutics, Inc. VRDN | Cormorant Asset Management LP | 1,100,000 2.73% | -336,322 (-23.42%) | View |
| 2023-02-14 2:23 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | TCG Crossover GP I LLC | 983,610 2.4% | 983,610 (New Position) | View |
| 2023-02-14 11:43 am Purchase | 13G | Viridian Therapeutics, Inc. VRDN | BIOTECHNOLOGY VALUE FUND L P | 2,302,094 5.6% | 99,779 (+4.53%) | View |
| 2023-02-14 08:59 am Purchase | 13G | Viridian Therapeutics, Inc. VRDN | Deep Track Capital LP | 3,312,974 7.93% | 1,493,285 (+82.06%) | View |
| 2023-02-13 5:45 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | Vivo Opportunity LLC | 1,678,207 4.2% | 378,207 (+29.09%) | View |
| 2023-02-09 11:35 am Purchase | 13G | Viridian Therapeutics, Inc. VRDN | VANGUARD GROUP INC | 2,114,994 5.25% | 2,114,994 (New Position) | View |
| 2023-02-03 12:10 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | BlackRock Inc. BLK | 2,761,556 6.9% | 2,761,556 (New Position) | View |
| 2023-01-26 5:03 pm Sale | 13G | Viridian Therapeutics, Inc. VRDN | MILLENNIUM MANAGEMENT LLC | 785,854 2% | -636,623 (-44.75%) | View |
| 2022-08-19 4:34 pm Purchase | 13D | Viridian Therapeutics, Inc. VRDN | Fairmount Funds Management LLC | 9,192,814 19.99% | 5,732,463 (+165.66%) | View |
| 2022-08-12 12:35 pm Sale | 13G | Viridian Therapeutics, Inc. VRDN | Frazier Life Sciences Public Fund L.P. | 300,000 1.1% | -1,205,200 (-80.07%) | View |
| 2022-05-31 4:40 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | MILLENNIUM MANAGEMENT LLC | 1,422,477 5.1% | 1,422,477 (New Position) | View |
| 2022-05-19 4:30 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | COMMODORE CAPITAL LP | 1,371,339 5% | 1,371,339 (New Position) | View |
| 2022-02-14 4:32 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | Point72 Asset Management L.P. | 472,864 2.2% | 46,702 (+10.96%) | View |
| 2022-02-14 4:19 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III L.P. | 2,205,268 9.99% | 262,213 (+13.49%) | View |
| 2022-02-14 4:11 pm Sale | 13G | Viridian Therapeutics, Inc. VRDN | RA CAPITAL MANAGEMENT L.P. | 0 0% | -388,385 (Position Closed) | View |
| 2022-02-14 4:05 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | D. E. SHAW & CO L.P. | 764,613 3.5% | 44,240 (+6.14%) | View |
| 2022-02-14 3:04 pm Purchase | 13G | Viridian Therapeutics, Inc. VRDN | Cormorant Asset Management LP | 1,436,322 6.28% | 977,178 (+212.83%) | View |
| 2022-02-14 2:47 pm Sale | 13G | Viridian Therapeutics, Inc. VRDN | Logos Global Management LP | 0 0% | -1,495,000 (Position Closed) | View |